Navigation Links
Study Results of Novocure's NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
Date:5/21/2012

rogression-free survival rate at six months was 21.4% and 15.1% (p=0.13), in NovoTTF and active control patients, respectively.  Radiological responses were comparable (14% versus 9.6%, p=0.19), with 3% complete responses seen only in the NovoTTF arm.

The most common NovoTTF-related adverse events were principally mild (14%) to moderate (2%) skin rash beneath the device's transducer arrays.  Severe adverse events occurred in 6% of patients treated with NovoTTF vs 16% for those treated with chemotherapy (p=0.02).  Quality of life analyses favored NovoTTF therapy in most domains, including vomiting, nausea, pain, diarrhea, constipation, and cognitive and emotional functioning.

"The patients treated within this trial had very, very advanced disease. Most of our patients rapidly become independent in handling the device and loved having a treatment without the need for chemotherapy," said Dr. Roger Stupp of the University of Lausanne, lead author of the study.  "We are encouraged by our findings and the future groundbreaking potential of NovoTTF therapy in this tough-to-treat disease and other cancer."

The study's co-principal investigator Dr. Philip Gutin, Chair of the Department of Neurosurgery and Co-Executive Director of the Brain Tumor Center at Memorial Sloan Kettering Cancer Center in New York said, "Patients who have GBM face significant challenges, and we as physicians currently have limited treatment options.  This study shows that a new, safe and effective treatment option is now available."

"The results of this important trial clearly show that a fourth treatment modality now exists for patients with recurrent GBM," said Asaf Danziger, Novocure's Chief Executive Officer. "We are working closely with many of the leading cancer centers in the world to make NovoTTF therapy available to their patients, and will continue to develop this new cancer fighting weapon to improve the lives of people suffering f
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
2. First, do no harm: Study finds danger in standard treatment for a serious lung disease
3. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
6. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. New Study Shows Long-Term Effects of Drug Prevention
9. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... HILL, N.C. , Jan. 23, 2015 For the ... are in dealing with payers. Likewise, the importance of the ... - will only continue to grow as payer formularies and ... access therapies. At the same time, managed markets ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... "Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends ... Video communication has been the topic of fascination ... the United States and the Soviet Russia. Earlier ...
(Date:1/23/2015)... , Jan. 23, 2015 Research and Markets ... the "Urinary Catheters Market (Indwelling or Foley Catheters, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... , At present, the global market for ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Data Show Bifeprunox Maintained Stability,Significantly Longer than ... Profile Comparable with Placebo , MARIETTA, Ga. ... Solvay,Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of ... results on,bifeprunox, an investigational treatment for adult ...
... 2007 /PRNewswire-FirstCall/ -- Forest,Laboratories, Inc. and Cypress ... from a 1,196 patient randomized,three month, double-blind, ... therapeutic effects of,milnacipran as a treatment of ... only been able to review initial top-line,results ...
Cached Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:1/22/2015)... (PRWEB) January 22, 2015 Woodloch Pines, an ... has been selected by TripAdvisor as the number one best ... 6th best in the world for their annual Travelers’ Choice ... travel community . The website is home to millions of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining the ... . , Auto insurance quotes help many drivers find ... necessary to call an agent or visit an agency for ... single website: http://autocarinsurancebest.com/ . , Every business who relies ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... number one in the nation in cardiology and GI ... for 2008, BOSTON, May 29 Children,s Hospital ... pediatric hospitals in the country,according to U.S.News & World ... Since the magazine began ranking hospitals 19 years ago, ...
... 5; Cancer program ... in Top 10 ... Bay Area, STANFORD, Calif., May 29 Once again, Lucile Packard,Children,s Hospital ... annual America,s Best Children,s Hospitals issue hitting,newsstands June 2, the magazine places Lucile ...
... to 66% increased risk of disease after operation , , ... anti-rejection drug sirolimus may lead to increased risk of ... data on about 20,000 Medicare patients who had kidney ... patients had diabetes before their kidney transplant. Compared to ...
... Sales Managers and executives,often face questions such as: ... middle-ranking performers, Inducements have to stand out to,engender ... is a summary of a research,presentation that evaluates ... and intangible rewards used in sales recognition programs. ...
... 1 or type 2 diabetes who self-monitor their blood ... adjust treatment regimens can achieve improved glucose control, according ... Special Supplement to the June 2008 issue (Volume 10, ... journal published by Mary Ann Liebert, Inc. ( www.liebertpub.com ...
... May 29 Martek Biosciences,Corporation (Nasdaq: MATK ) ... Annual Needham & Company Biotechnology and Medical Technology,Conference in ... - 12, 2008 at,the New York Palace Hotel. Peter ... 12, 2008 at 1:30 p.m. Eastern Time., A ...
Cached Medicine News:Health News:Children's Hospital Boston Ranked Number One in New England 2Health News:Children's Hospital Boston Ranked Number One in New England 3Health News:U.S.News 2008 'Best Hospitals' Issue Again Ranks Packard Children's as One of Nation's Best 2Health News:Anti-Rejection Drug May Boost Diabetes in Kidney Transplant Patients 2Health News:Best Practices in Sales Recognition 2Health News:Special supplement on self-monitoring of blood glucose in diabetes technology & therapeutics 2
... blood oximeters provide cardiologists with critical ... a patient's blood. The Oxicom series ... over a half-million saturation samples measured ... cost-effective oxygen saturation readings in less ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: